Minerva cardiology and angiology最新文献

{"title":"Future of factor XI inhibitors in cardiovascular practice.","authors":"Antonio Greco, Nicola Ammirabile, Davide Landolina, Antonino Imbesi, Carmelo Raffo, Davide Capodanno","doi":"10.23736/S2724-5683.23.06474-8","DOIUrl":"10.23736/S2724-5683.23.06474-8","url":null,"abstract":"<p><p>Anticoagulation is indicated for treatment and prevention of arterial and venous thrombosis. Targeting different steps of the coagulation process, currently available anticoagulants entail an increased risk of bleeding, which detrimentally impacts on prognosis and hinders the administration of an effective antithrombotic regimen. Factor XI (FXI) inhibition has emerged as a strategy to uncouple prevention of thrombosis from bleeding. Indeed, while FXI is crucial for the amplification phase in pathological thrombosis, it is ancillary in physiological hemostasis. A comprehensive search in several scientific databases has been performed to identify relevant studies in the field. In addition, ongoing trials have been searched for in proper datasets to provide an updated and comprehensive assessment of the current state of investigations on FXI inhibition. Many compounds have been tested to inhibit FXI at different stages (i.e., synthesis, activation, or interactions with target molecules and coagulation factors). These include antisense oligonucleotides, monoclonal antibodies, small molecules, natural peptides and aptamers. In phase 2 studies, FXI inhibitors reduced thrombotic complications without any corresponding increase in bleeding. FXI inhibitors were noninferior and potentially superior to low-molecular-weight heparin in orthopedic surgery and reduced bleeding compared to apixaban in patients with atrial fibrillation. FXI inhibition is also under testing in other conditions, including end-stage renal disease, cancer, or noncardioembolic stroke. FXI inhibition represents a promising and rapidly emerging approach for a number of clinical indications. This article reviews the rationale, evidence, pharmacology, and future applications of FXI inhibition.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"201-218"},"PeriodicalIF":1.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective comparative study of guiding catheters for elective percutaneous coronary interventions for simple circumflex lesions: active vs. passive support.","authors":"Yeliz Guler, Cevat Kirma","doi":"10.23736/S2724-5683.24.06731-0","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06731-0","url":null,"abstract":"<p><strong>Background: </strong>In percutaneous coronary interventions (PCI), the ability to anticipate procedural challenges and a comprehensive knowledge of specialized equipment are paramount. Among these, the choice of guide catheters is crucial. A retrospective analysis was conducted on patients who underwent elective PCI procedures targeting type A and B1 circumflex artery lesions.</p><p><strong>Methods: </strong>A total of 311 patients were categorized into two groups based on selection of guiding catheter: Group-1 used passive support catheters, whereas Group-2 employed standard Judkins catheters. We assessed the differences in procedural duration and characteristics, and contrast medium dosage between the two groups.</p><p><strong>Results: </strong>In the Group-2, the utilization of extra support wire (7.8% vs. 17.3%, P=0.023), repeated predilatation (6.8% vs. 15.4%, P=0.031), and guide catheter exchange (2.9% vs. 9.1%, P=0.044) was more prevalent. Additionally, in the Group-2, the amount of contrast agent used was higher (146±43 vs. 110±37, P<0.001) and the procedure duration was longer (35±16 vs. 25±8, P<0.001).</p><p><strong>Conclusions: </strong>In our study, when comparing the use of a Judkins catheter to a passive support catheter for type A/B1 circumflex artery lesions, the group utilizing the passive support catheter exhibited advantages in terms of procedure duration, usage of interventional materials, and contrast consumption. The choice of the guide catheter plays a pivotal role in performing PCI.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota diversity and composition in patients with atherosclerosis analyzed using full-length 16S rRNA gene sequencing.","authors":"Shi-Kui Guo, Yu Xu, Shang-Tai Dai, Yong-Zhi Wang, Jian Zhang, De-Zhi Hou, Rou-Gang Li, Kun-Mei Gong","doi":"10.23736/S2724-5683.24.06591-8","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06591-8","url":null,"abstract":"<p><strong>Background: </strong>Gut microbiota have been linked to atherosclerosis (AS). This study aimed to investigate the differences in gut microbiota between patients with AS and healthy controls using third-generation gene sequencing.</p><p><strong>Methods: </strong>Full-length 16S rRNA amplicon sequencing was used to compare the composition, abundance, diversity, and differences in intestinal flora between a healthy control group (ASC, N.=20) and an atherosclerotic patient group (ASP, N.=21).</p><p><strong>Results: </strong>The ASP group showed higher rank richness and an altered microbial community structure compared to the control group. We found 12 phyla and 201 bacterial taxa in our samples, with Firmicutes being the most abundant phylum in both groups. However, several bacterial species, including Lactobacillus fermentum, Escherichia coli, Dialister succinatiphilus, and Fusobacterium varium, were more abundant in the ASP group. Except for Escherichia coli, the other three bacterial species are associated with lipid metabolism. The ASP group exhibited smaller network diameters, lower graph density, and lower average degree than the ASC group, indicating greater correlations and clustering of operational taxonomic units samples. Functional profiling showed significant enrichment in AMPK signaling pathway and glucose metabolism in the ASC group, while bacterial invasion of epithelial cells was enriched in the ASP group.</p><p><strong>Conclusions: </strong>Our findings aid in enhancing the comprehension of the gut microbiota's role in AS development and provide valuable insights for potential therapeutic interventions.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life and ischemia assessment in coronary chronic total occlusions: does treatment strategy really matter?","authors":"Lazzaro Paraggio, Sebastiano Sciarretta, Marco Bernardi","doi":"10.23736/S2724-5683.25.06671-2","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06671-2","url":null,"abstract":"","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total cholesterol level decrease predicts higher mortality in chronic heart failure.","authors":"Mariana Matos, Ana Neves, Sérgio Madureira, Rita Gouveia, Catarina Elias, Helena Rocha, Maria I Matos, Adriana Costa, Francisca Correira, Helena Hipólito-Reis, Catarina Reis, Marta Patacho, Jorge Almeida, Patrícia Lourenço","doi":"10.23736/S2724-5683.24.06738-3","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06738-3","url":null,"abstract":"<p><strong>Background: </strong>In heart failure (HF), lower total cholesterol (TC) levels associate with poor outcomes. Whether TC variations portend prognostic implication is unknown. We aimed to evaluate the impact of TC variation in HF.</p><p><strong>Methods: </strong>We retrospectively analyzed adult outpatients with chronic HF with systolic dysfunction evaluated between January/2012 and December/2020. Patients with no TC measurement at baseline or at the 1-year follow-up visit were excluded. Variation of TC during the first year = [(baseline TC - TC at the 1-year visit)/baseline TC] × 100. Patients were followed-up until five years after the first-year visit.</p><p><strong>Endpoint: </strong>all-cause mortality. A Cox-regression analysis was performed to assess the association of TC variation (cutoff ≥10% decrease) with mortality. A multivariate model was built.</p><p><strong>Results: </strong>We studied 362 patients, 67.4% male, mean age 69 years, 42.8% presented severe systolic dysfunction; 69.6% were on statin therapy. TC level decreased during the first year: 173 (47) vs. 166 (45) mg/dL respectively (P=0.002). In 127 (35.1%) patients there was a ≥10% decrease in TC. During a median follow-up of 57 (31-60) months, 130 (35.9%) patients died: 41.7% in those with a ≥10% TC decrease versus 32.8% in the remaining (P=0.09). Patients with at least 10% decrease in TC had higher mortality risk, after a multivariate adjustment the HR of all-cause death was 1.71 (1.15-2.55, P=0.008).</p><p><strong>Conclusions: </strong>Patients with ≥10% decrease in TC had an independent 71% increase in the risk of death. Our results reinforce the cholesterol paradox and further question the use of statins in HF.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can genetic factors be useful to predict cardiovascular toxicity in patients with oncohematological diseases?","authors":"Kristina Kopeva","doi":"10.23736/S2724-5683.25.06828-0","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06828-0","url":null,"abstract":"","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular toxicity in patients with oncohematological diseases: genetic predictors study.","authors":"Geliya Gimatdinova, Olesya Danilova, Igor Davydkin, Yuliya Milyutkina, Alexey Sustretov, Giuseppe Galati, Elena Cavarretta, Mariangela Peruzzi, Olga Germanova","doi":"10.23736/S2724-5683.24.06748-6","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06748-6","url":null,"abstract":"<p><strong>Background: </strong>The aim is of this study to identify genetic single nucleotide polymorphisms associated with cardiovascular (CV) toxicity in patients of oncohematological profile receiving antitumor immune chemotherapy.</p><p><strong>Methods: </strong>In single-center prospective study were included 34 patients with the diagnosis of non-Hodgkin's B-cell follicular lymphoma. All of them received R-CHOP scheme immune chemotherapy. Patients were divided into two groups up to the appearance of CV toxicity during the treatment: main group - patients with CV toxicity (mean age 42.4±2.8, three men [25%]), control group - without it (mean age 39.8±1.7, of which eight men [36%]). CV toxicity has been defined by the presence of CV symptoms associated to a reduction of left ventricular ejection fraction (LVEF) >10% from baseline or in absolute lower than 53% and/or a decrease in LV longitudinal strain >12% from baseline and/or an increase in NT-proBNP>125 pg/mL.</p><p><strong>Results: </strong>This study presents the identified genetic features in patients with an oncohematological profile in the context of the occurrence of CV toxicity during the treatment of malignant neoplasms. Variants rs1879257 of the ABCC5 gene, rs13224758 of the PRKAG2 gene, rs10925391 of the RYR2 gene and rs4149178 of the SLC22A7 gene significantly increased the risk of developing CV toxicity in the target group of patients by 5-6 times. In addition, the study showed that the rs2032582 ABCB1 gene and rs3729856 GATA4 gene variants had the opposite effect and reduced the risk of developing CV complications, having a protective effect on the CV system.</p><p><strong>Conclusions: </strong>The results of this study endorse the possibility of performing a genetic screening before anticancer immunochemotherapy as a future tool for stratifying patients with an oncohematological profile and minimizing CV toxicity. However, further studies are needed to confirm the diagnostic and prognostic role of the above identified genetic variants.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing acute and chronic heart failure patients: the Jordanian Heart Failure Registry (JoHFR).","authors":"Hanna Al-Makhamreh, Kais Al-Balbissi, Akram Al-Saleh, Mahmoud Izraiq, Ahmad A Touabsi, Sarah Al-Qalalweh, Mohammad Y Mahmoud, Louis Hobeika, Toqa Awaisheh, Farah Albustanji, Yazan Y Obaid, Hind Abu Tawileh, Ghasaq Saleh, Hadi Abu-Hantash","doi":"10.23736/S2724-5683.24.06659-6","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06659-6","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is a clinical syndrome with different signs and symptoms that present in chronic and acute forms. This study aimed to compare acute HF (AHF) and chronic HF (CHF) regarding demographics, baseline characteristics and comorbidities, and clinical outcomes.</p><p><strong>Methods: </strong>This study is a sub-analysis of the Jordanian HF registry (JoHFR). A total of 21 medical centers representing a diverse range of medical facilities participated in the study. The studied data included demographics, medical history, comorbidities, HF risk factors, and clinical outcomes.</p><p><strong>Results: </strong>The study involved 2151 HF patients. Patients with AHF were more likely to be to have diabetes (P=0.001), history of premature ASCVD (P<0.001), and treated at university-based hospital (P<0.001) while they were less likely to be males (P<0.001) and have family history of premature ASCVD (P=0.001) compared to patients with CHF. The AHF group had a higher percentage of patients having more than two office visits or hospital admissions related to HF in the last 12 months (17.5% vs. 10.1%; P<0.001). AHF patients also registered higher percentages in mechanical ventilation requirement (6.6% vs. 3.3%; P=0.005) and mortality rates (11.4% vs. 8.7%; P=0.049).</p><p><strong>Conclusions: </strong>This study revealed significant differences in the characteristics and outcomes of AHF and CHF using data from the largest HF registry in the Middle East providing a solid foundation for future studies aimed to improve heart failure outcomes in the region.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implications of Body Mass Index and sarcopenic obesity in patients with severe aortic stenosis.","authors":"Cristian M Garmendia, Ignacio M Seropian, Juan I Damonte, Horacio Medina Del Chazal, Vadim Kotowicz, Mariela Cal, Maximiliano Smietniansky, Mariano Falconi, Carla R Agatiello","doi":"10.23736/S2724-5683.24.06577-3","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06577-3","url":null,"abstract":"<p><strong>Background: </strong>Aortic valve stenosis (AS) often coexists with various comorbidities and concurrent cardiovascular risk factors. However, the clinical impact of obesity, considering sarcopenia, remains unexplored in patients with severe symptomatic AS evaluated by a Heart Team. This study evaluates Body Mass Index (BMI)'s discriminative power and clinical implications regarding adverse clinical events in severe symptomatic AS patients assessed by a Heart Team, while considering sarcopenia.</p><p><strong>Methods: </strong>This retrospective single-center cohort study included severe symptomatic AS patients evaluated by a Heart Team, analyzing baseline characteristics, anatomo-functional data, biochemical parameters, and adverse clinical events during a 2-year follow-up. The cohort was stratified by BMI and the presence of sarcopenia, determined using the validated SARC-F Questionnaire.</p><p><strong>Results: </strong>The mean age of the study cohort (N.=278) was 83.25±6.88 years (51.1% female), with a median follow-up of 13.05 months (IQR 5.96-24.50). The AUC for the primary outcome related to BMI was 0.623 ([95% CI 0.543-0.704]; P=0.004), with the optimal BMI threshold at 24.95 kg/m². Patients with a BMI>24.95 kg/m² exhibited improved survival (HR 0.508 [95% CI 0.303-0.853]; P=0.010). Conditional dependence regarding the presence of sarcopenia was observed in the relationship between BMI and adverse clinical events (sarcopenic patients, P=0.015 vs. non-sarcopenic, P=0.618; Cochran-Mantel-Haenszel test P=0.171).</p><p><strong>Conclusions: </strong>Among severe symptomatic AS patients evaluated by a Heart Team, BMI predicts adverse clinical outcomes. Remarkably, normal-weight patients have higher mortality rates than obese patients. This association was only evident in the absence of sarcopenic obesity.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value and regulatory role of long non-coding RNA MIR210HG in hypertension.","authors":"Wenxin Zhao, Yajing Zheng, Yuanyuan Su, Runxi Xu, Shuqi Huang, Chong Yang, Yunhua Hao, Zhichao Bi","doi":"10.23736/S2724-5683.24.06692-4","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06692-4","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is the most prevalent chronic disease globally and the treatment and control ratio of hypertension patients are still low. The function of lncRNA MIR210HG in hypertension has not yet been announced.</p><p><strong>Methods: </strong>Eighty-three hypertension patients and 79 healthy individuals were enrolled. The Human Umbilical Vein Endothelial Cells (HUVECs) treated with Ang II were employed to imitate hypertension. The relative expression of MIR210HG and miR-125b-5p were evaluated by qRT-PCR while the ROC curve was applied to assess the diagnostic performance of MIR210HG. The CCK-8 assay was performed to detect the proliferation ability. The transwell assay and flow cytometry were used to analyze the migratory or apoptosis, respectively. The dual luciferase reporter system was used to confirm the targeted relationship between MIR210HG and miR-125b-5p.</p><p><strong>Results: </strong>Up-regulated MIR210HG was found in hypertension patients (P<0.001) compared to healthy individuals and the upregulation was positively associated with the severity of hypertension (P<0.01). Up-regulated MIR210HG exhibited a promising diagnosability for hypertension patients. The area under the ROC curve was 0.8765 with high sensitivity (81.93%) and specificity (83.28%). In hypertension cell model, increased MIR210HG was observed along with declined cell proliferation, migration and enhanced apoptosis, which were reversed by MIR210HG knockdown. MIR210HG knockdown also inhibited inflammation levels including TNF-α, IL-1β and IL-6. The miR-125b-5p was a potential downstream target of MIR210HG and they were negatively correlated in expression.</p><p><strong>Conclusions: </strong>Up-regulated MIR210HG was a promising diagnostic biomarker in identifying hypertension patients. MiR-125b-5p was a potential downstream target of MIR210HG in HUVECs.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}